UROLIZER® - RAUMEDIC® sets the standard for assessing urinary stone formation risks |
With the UROLIZER you have a precise, fast and simple to handle device to assess your patients' risk of forming urinary stones via the BONN-Risk-Index (BRI). The BRI is a reliable method for assessing a patient's risk of forming urinary stones (calcium oxalate stones), developed by the department for experimental urology (Manager: Dr. N. Laube, Director: Prof. Dr. S. C. Müller) of the clinic and polyclinic for urology in Bonn. RAUMEDIC implemented the application of this method in clinics and surgeries with the development of the analysis device UROLIZER.
The UROLIZER is particularly suitable for characterising the base risk of the stone patient (prior to therapy) and for monitoring the success of metaphylaxis. Beyond this it can support the patient's compliance with metaphylaxis and support the identification of persons at risk (prophylaxis).
The BONN-Risk-Index (BRI) is the measured result of a standardised in-vitro test used to assess the crystallisation risk of calciumoxalate in the urine.
This process initiates artificial crystallisation of the native urine sample to be tested. As all urine components contribute to the crystallisation result, the BRI is a marker for the balance or imbalance between promoters and inhibitors of urinary stone formation.
| 
|
Award for UROLIZER
In December 2004 the RAUMEDIC development partner (NTTF, Rheinbreitbach), was awarded the 2. prize of the innovation awards of the county of Rheinland-Pfalz for the development of the Urolizer.
| 
Award for Urolizer
|
UrolithiasisAccording to latest research urinary stone disease has a prevalence on Germany of 4.7%. In 2000 9.7% of men and 5.9% of women over 50 years of age suffered from urinary stones. Acute cases rose in 2000 to three times the levels in 1979. This development is observed in all leading industrialised nations as well as in all countries with increasingly westernised eating and drinking habits. The relapse rate with a large proportion of multiple relapses is between 40% and 60%. The illness occurs first between the ages of 20 to 50 years. 70-75% of stones consist of calcium oxalate.
|
|
Further Reading:
Hesse A., Brändle E., Wilbert D., Kohrmann K.U., Alken P.: Study on Prevalence and Incidence of Urolithiasis in Germany comparing the years 1979 vs. 2000. Eur Urol, 44: 709, 2003
Laube N., Schmidt M.E., Hesse A.: Die Überwachung des Behandlungserfolgs von Kalzium-Oxalat-Steinpatienten mit Hilfe des BONN Risk Index. Urologe(A), Januar 2003
Laube N., Hergarten S., Hoppe B., Schmidt M, Hesse A.: Determination of the Calcium Oxalate Crystallization Risk from Urine Samples: The BONN Risk Index in Comparison to Other Risk Formulas. J Urol, 172: 355-359, 2004.
Laube N., Schneider A., Hesse A.: A New Approach to Calculate the Risk of Calcium-Oxalate Cystallization from Unprepared Native Urines. Urol. Res. 2000; 28:274-80
|
|
Links:
www.bonn-risk-index.de
www.expuro.uni-bonn.de
|
|
